Double-Crane bets on Lier Chemical while earnings slip and drug pipeline grows
5.66 billion yuan Lier Chemical acquisition Double-Crane won the bid to buy 23.5% of Lier Chemical for 5.656 billion yuan cash, becoming its controlling shareholder. This expands into pesticides and synthetic biology, a long-term growth bet, though it uses a lot of cash and is a major restructuring.
This is the biggest new event of the period and the main force behind the stock's story.
Interim profit and revenue fall First-half 2026 net profit was 946 million yuan, down 3.43%, and revenue fell 3.44% to 5.615 billion yuan. This shows the core business is under pressure, a real counterweight to the acquisition and pipeline news.
It is the key financial result of the period and the main negative force on the stock.
New drug approvals and trial progress The company completed a Phase III trial for pregabalin extended-release tablets and received approvals for acetazolamide capsules, sodium lactate Ringer's irrigation solution, lomustine capsules, and ezetimibe/atorvastatin tablets. These add future revenue sources.
A steady stream of pipeline wins supports long-term growth even as current earnings dip.
Dividend and procurement selection Double-Crane paid a cash dividend of 3.79 yuan per 10 shares and had products proposed for selection in the 12th national centralized drug procurement. Both are shareholder-friendly and support sales volume, though price cuts from procurement can pressure margins.
These are new capital-return and demand-side events that affect investor income and product demand.